3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le jeudi 7 novembre 2019
Doi : 10.1016/j.jaad.2019.07.103
accepted : 30 July 2019
Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis

Ming-Ying Wu, MD a, d, Chia-Ling Yu, MS b, Shih-Jyun Yang, MD a, e, Ching-Chi Chi, MD, MMS, DPhil, FAAD a, c,
a Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 
b Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 
c College of Medicine, Chang Gung University, Taoyuan, Taiwan 
d Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan 
e Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan 

Reprint requests: Ching-Chi Chi, MD, MMS, DPhil, FAAD, Department of Dermatology, Chang Gung Memorial Hospital, Linkou, 5, Fuxing St, Guishan Dist, Taoyuan 33305, Taiwan.Department of DermatologyChang Gung Memorial HospitalLinkou, 5, Fuxing St, Guishan DistTaoyuan33305Taiwan

Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain.


To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics.


We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias.


We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor α inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics.


Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic.


Tumor necrosis factor α inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients.

The full text of this article is available in PDF format.

Key words : anti-interleukin-12/23 biologic, anti-interleukin-17 biologic, biologic therapy, body mass index, body weight, network meta-analysis, psoriasis, tumor necrosis factor inhibitor

Abbreviations used : BMI, CI, IL, MD, SD, SUCRA, TNF-α, TNFi

 Funding sources: None.
 Conflicts of interest: Prof Chi received speaking fees from AbbVie Taiwan, Janssen Taiwan, Novartis Taiwan, and Pfizer Taiwan. Dr Wu, Ms Yu, and Dr Yang have no conflicts of interest to disclose.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline